Quarterly consolidated sales at 2.7 million euros
Positive EBITDA at 0.3 million euros / Positive operating
cash flow at 0.5 million euros
Consolidated available cash at 4.8 million euros as of March
31, 2021 increasing by 0.6 million euros
Regulatory News:
MEMSCAP (NYSE Euronext: MEMS), the leading provider of
innovative solutions based on MEMS (micro-electro-mechanical
systems) technology, today announced its earnings for the first
quarter ending March 31, 2021.
Analysis of the consolidated income statement
Consolidated revenue for the first quarter of 2021 was 2.7
million euros (3.3 million US dollars) compared to 3.4 million
euros (3.7 million US dollars) for the first quarter of 2020 and
2.7 million euros (3.2 million US dollars) for the fourth quarter
of 2020.
Consolidated revenue distribution by market segment, over the
first quarter of 2021, is as follows:
Market segments / Revenue (In
million euros) – Non-audited
Q1 20
%
Q1 21
%
Aerospace
1.8
54%
0.9
33%
Optical communications / Adaptive
optics
1.1
33%
0.5
17%
Medical / Biomedical
0.4
11%
1.3
48%
Others
0.1
2%
0.1
2%
Total
3.4
100%
2.7
100%
(Any apparent discrepancies in totals are due to rounding.)
MEMSCAP’s consolidated earnings for the first quarter of 2021
are given within the following table:
In million euros –
Non-audited
Q1 20
Q1 21
Revenue
3.4
2.7
- Standard products*
- Custom products
2.2
1.2
2.2
0.6
Cost of revenue
(2.4)
(2.0)
Gross margin
1.0
0.8
% of revenue
29%
28%
Operating expenses**
(1.0)
(0.9)
Operating profit / (loss)
(0.0)
(0.1)
Financial profit / (loss)
0.0
(0.0)
Income tax expense
(0.0)
(0.0)
Net profit / (loss)
(0.0)
(0.1)
(Any apparent discrepancies in totals are due to rounding.) *
Including the royalties from the dermo-cosmetics segment. ** Net of
research & development grants.
Sales for the first quarter of 2021 confirmed the positive trend
of the medical business (sales multiplied by 3.5 vs. the first
quarter of 2020, thus an increase of + 0.9 million euros). The high
level of sales in the medical business, in line with the fourth
quarter of 2020, compensated the weak demand in the avionics
business, which remains affected by the Covid-19 pandemic (-0.9
million euros vs. the first quarter of 2020). However, the avionics
business increased by +0.1 million euros compared to the fourth
quarter of 2020. The optical communications business was down by
0.6 million euros vs. the first quarter of 2020 but started to
recover compared to the fourth quarter of 2020 (+0.2 million euros
vs. the fourth quarter of 2020). This recovery was still impacted
by the ongoing maintenance imposed by the technical incident on an
industrial equipment occurred in the US facilities in the fourth
quarter of 2020.
The strategy of diversifying the Group's activities around 3
business areas thus mitigated the impacts of a deeply deteriorated
economic environment.
* * *
The Group's gross margin rate stood at 28% of consolidated sales
compared to 29% for the first quarter of 2020.
Operating expenses decreased to 0.9 million euros compared to
the amount of 1.0 million euros for the first quarter of 2020.
The Group therefore reported operating and net losses at 0.1
million euros for the first quarter of 2021 compared to breakeven
operating and net earnings for the first quarter of 2020.
For the first quarter of 2021, the Group posted a positive
EBITDA at 0.3 million euros, similarly to the first quarter of
2020. In addition, the control of the consolidated working capital
requirement led to a positive operating cash flow of 0.5 million
euros for the first quarter of 2021.
On March 31, 2021, the Group reported a significant increase of
available cash which amounted at 4.8 million euros including cash
investments (Corporate bonds) recorded under non-current financial
assets (vs. 4.2 million euros at December 31, 2020). In addition to
this amount, the available unused credit lines amounted to 0.4
million euros on March 31, 2021.
* * *
Analysis and perspectives
The first quarter of 2021 confirmed the positive trend of the
medical business, compensating for the weak demand in the avionics
business which remains affected by the Covid-19 pandemic. As
previously mentioned, the diversity of its businesses allows
MEMSCAP to face the effects of such a major health and economic
crisis, particularly impacting the avionics sector even if a slight
recovery of this business seems to be observed.
The control of operating expenses and the working capital
requirement reflected the Group’s capacity to adapt and led to an
unaudited consolidated EBITDA of +0.3 million euros and an
operating cash flow of +0.5 million euros for the quarter. Thus,
consolidated available liquidities amounted to 4.8 million euros as
of March 31, 2021.
However, the potential impact of the pandemic remains very
uncertain based on the current available information. MEMSCAP will
continue to regularly assess the impact of Covid-19 on its
business.
MEMSCAP pursues its strategy focused on avionics, medical and
optical communications segments, backed by its own intellectual
property, as well as the development of an increased flexibility of
its production capacities.
* * *
MEMSCAP general shareholders’ meeting: May 28, 2021.
Q2 2021 earnings: July 29, 2021.
About MEMSCAP
MEMSCAP is the leading provider of innovative
micro-electro-mechanical systems (MEMS)-based solutions.
MEMSCAP’s products and solutions include components, component
designs (IP), manufacturing and related services.
MEMSCAP is listed on Euronext Paris ™ - Segment C - ISIN:
FR0010298620 - MEMS.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210426005677/en/
Yann Cousinet Chief Financial Officer Ph.: +33 (0) 4 76 92 85 00
yann.cousinet@memscap.com
For more information, visit our website at:
www.memscap.com.
Grafico Azioni Memscap (EU:MEMS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Memscap (EU:MEMS)
Storico
Da Apr 2023 a Apr 2024